LENZ Therapeutics has partnered with Sarah Jessica Parker to launch “Make it VIZZable,” a nationwide consumer awareness initiative for VIZZ™ (aceclidine ophthalmic solution) 1.44%. The campaign will feature Parker sharing her personal experience with age-related blurry near vision and demonstrating how once-daily VIZZ drops restore functional near vision for up to ten hours. VIZZ is available by prescription from eye care professionals and is being supported with free in-office sample offers. The company estimates that 128 million Americans over 45 are affected by presbyopia and expects the campaign to drive significant patient inquiry and eye-doctor visits in key metropolitan markets, including New York City, Los Angeles and Chicago.

Seven research firms covering LENZ Therapeutics have issued a consensus recommendation of Moderate Buy, with five Buy ratings, one Hold and one Sell. The average 12-month target price stands at $56.40. Analysts cite the successful CLARITY Phase 3 trial in which 93% of participants achieved 20/40 or better near vision within 30 minutes and maintained improvement for up to ten hours. They believe VIZZ’s differentiated mechanism—a predominantly pupil-selective miotic producing a sub-2mm pupil ‘pinhole effect’—positions LENZ to capture a significant share of the presbyopia market, forecast to exceed $4 billion annually in the United States alone.